United Kingdom Pharmaceuticals and Healthcare Report Q1 2010

Executive Summary .....................5
SWOT Analysis......6
UK Pharmaceuticals And Healthcare Industry SWOT....................... 6
UK Political SWOT.............................. 7
UK Economic SWOT ........................... 8
Pharmaceutical Business Environment Rating .......................9
Table: Western Europe – Regional Pharmaceuticals Business Environment Ratings For Q110 ...... 9
Limits of Potential Returns ................ 10
Risks to Realisation of Returns .......... 10
UK – Market Summary ...............12
Regulatory Regime.....................14
EU Regulatory Developments............ 15
Recent Regulatory Developments ............................. 16
Recent NICE Recommendations ........ 17
Innovative Medicines ......................... 19
Generic Medicines ............................. 19
OTC Medicines ........... 20
Intellectual Property Issues ............... 21
Counterfeit Pharmaceuticals ............. 23
Table: Examples Of Recalls Of Counterfeit Medicines In The UK .......................... 23
Pricing Regime ........... 25
Generic Prices ............ 27
OTC Prices ................. 28
Reimbursement Regime...................... 28
Industry Developments..............30
Epidemiology.............. 30
Non-Communicable Disease.............. 30
Communicable Disease...................... 32
Healthcare Sector .............................. 33
Healthcare Financing........................ 34
Health Insurance ........ 36
Health Tourism........... 37
Wholesale Sector ........ 38
Recent Wholesale Sector Developments.................... 40
Retail Sector ............... 41
Table: Registered Pharmacy Premises In The UK (2007) ............... 42
Parallel Imports.......... 43
Research and Development Sector............................ 45
Biotechnology ............. 47
Clinical Trials............. 47
Medical Devices.......... 48
Industry Forecast Scenario ........50
Overall Market Forecast.................... 50
Key Growth Factors – Industry.......... 52
Key Growth Factors – Macroeconomic .................... 53
United Kingdom - Economic Activity........................ 54
Prescription Drug Market Forecast.......................... 55
Patented Market Forecast.................. 57
Generics Market Forecasts................ 59
OTC Market Forecast........................ 61
Pharmaceutical Trade Forecasts....... 63
Key Risks to BMI Forecasts ............... 65
Competitive Landscape.............66
Pharmaceutical Industry.................... 66
Recent Company Developments......... 66
Table: Leading Pharmaceutical Corporations in the UK by Market Share (2007)......................... 68
Table: Top Pharmaceutical Products in the UK (2007)................... 69
Table: Cost Of Prescriptions* Dispensed In Various Disease Areas (GBPmn)....... 70
Company Profiles.......................72
Leading Multinational Manufacturers ........................... 72
Pfizer .......................... 72
Novartis ...................... 74
Sanofi-Aventis............. 76
Merck & Co ................ 78
Leading Indigenous Manufacturers ........ 80
GlaxoSmithKline......... 80
AstraZeneca................ 85
Country Snapshot: UK Demographic Data......88
Section 1: Population......................... 88
Table: Demographic Indicators, 2005-2030............. 88
Table: Rural/Urban Breakdown, 2005-2030 ............ 89
Section 2: Education and Healthcare ....................... 89
Table: Education, 2002-2005 ............ 89
Table: Vital Statistics, 2005-2030............................. 89
Section 3: Labour Market and Spending Power........ 90
Table: Employment Indicators, 2000-2005............... 90
Table: Consumer Expenditure, 2000-2011 (US$) ............................ 90
Table: Average Annual Wages, 2000-2012............... 91
BMI Methodology .......................92
How We Generate Our Pharmaceutical Industry Forecasts ................. 92
Pharmaceutical Business Environment Ratings Methodology .............. 93
Ratings Overview........ 93
Table: Pharmaceutical Business Environment Indicators ............... 94
Weighting.................... 95
Table: Weighting Of Components............................. 95
Sources ............................ 95
Forecast Tables ..........................96